Kengreal
Payments companies reported to CMS as associated with Kengreal. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kengreal, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kengreal
These are the largest totals companies reported as associated with Kengreal. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Megha Prasad | New York, NY | Cardiovascular Disease | $166,101.70 |
| Hayder Hashim | Washington, DC | Cardiovascular Disease | $42,129.01 |
| Jimmy Kerrigan | Nashville, TN | Interventional Cardiology | $39,663.29 |
| Garrett Wong | Sacramento, CA | Cardiovascular Disease | $31,915.78 |
| Shailendra Singh | Allentown, PA | Interventional Cardiology | $29,460.69 |
| Rohit Bhatheja | Orlando, FL | Cardiovascular Disease | $27,360.57 |
| Charles Gibson | Boston, MA | Interventional Cardiology | $21,840.00 |
| Christopher Degroat | Birmingham, AL | Cardiovascular Disease | $17,353.03 |
| Anand Prasad | San Antonio, TX | Interventional Cardiology | $15,417.85 |
| Srihari Naidu | Mineola, NY | Interventional Cardiology | $14,804.97 |
Prescribed Kengreal?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.